Compare BridgeBio Pharma Inc (BBIO) vs FMC Corp (FMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs FMC Corp — how do they compare? BridgeBio Pharma Inc trades at $82.34 (market cap $16.46B), while FMC Corp trades at $10.68 (market cap $1.34B). The key difference: BridgeBio Pharma Inc is far larger — about 12.3× FMC Corp's market cap, and FMC Corp pays a 2.99% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | FMC | |
|---|---|---|
Market Cap | $16.46B | $1.34B |
Sector | Health | Basic Materials |
52-Week High | $90.17 | $43.90 |
52-Week Low | $44.81 | $10.72 |
Enterprise Value | $18.02B | $5.49B |
Dividend Yield | — | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
FMC Corporation (FMC) trades at $10.91 with no change in the latest session. The agricultural sciences company shows mixed signals with a bearish technical outlook but positive analyst sentiment (47.6% buy ratings). Recent developments include a $400 million minority investment from Tessenderlo Group and regulatory submissions for new herbicide technology. However, fundamental challenges persist with negative net income margin of -72.93% and declining revenue from $5.8B in 2022 to $3.47B in 2025.
The stock presents a turnaround opportunity with attractive valuation metrics (P/S 0.4x, P/B 0.75x) and significant upside to the $16 consensus price target. Key risks include continued revenue declines, negative cash flow from operations, and high debt levels. The company's strategic moves to reduce debt and advance new products could drive recovery if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →
